The mood signal is the headline. Two divided doses a day of standardised extract, six weeks, and the depression score falls by about a third — better than placebo in every trial run, and level with fluoxetine head-to-head 1 2. Eleven trials pooled point the same way 3. The caveat: the trials are small and mostly Iranian, though Australian and Western replications came in positive too 4.
PMS is the cleanest win. In fifty women over two cycles, three-quarters on saffron had at least a 50% drop in symptom score; on placebo, one in twelve 5.
It rescues the side effect that makes people quit SSRIs. Adding 30 mg restored arousal, lubrication, and erectile function where placebo didn't — desire and orgasm less so 6 7.
Buy the extract, not the spice, and give it the full eight weeks.
Month two, if you respond. It's not a transformation; it's something specific given back.
- Low mood: by week six the morning weight has lifted, the workout you kept skipping is back on, and none of the SSRI trade-offs (weight, flatness, lost libido) showed up 3.
- PMS: by the second or third cycle the day-25 dip either doesn't come or loses its tooth 5.
- SSRI sexual side effects: intercourse mostly works again by about week four, arousal restored even if desire lags 7.
For roughly half of responders, that's enough to keep taking it.
The fine print — when to skip it, and what people get wrong
Not in pregnancy or while trying to conceive; high doses stimulate contractions, and no safety trial exists 8. In bipolar disorder, treat it like any antidepressant. Severe or treatment-resistant depression is a clinician conversation, not a supplement one.
The threads in your spice rack are not the supplement; the trials all use extract. It's not a gentle "natural SSRI" either — its reach is broader, and it's proven only for mild-to-moderate depression. The skin, hair, and energy claims have no trial backing.
Bulk saffron runs 30 to 40% adulterated with safflower or beet 9; a $5 "extract" with no standardisation may be mostly dyed plant matter. Buy HPLC-verified affron or Satiereal, and run it the full eight weeks.
- 1Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, et al. (2005). Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytotherapy Research. link
- 2Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH (2005). Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. Journal of Ethnopharmacology. link
- 3Marx W, Lane M, Rocks T, et al. (2019). Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. Nutrition Reviews. link
- 4Lopresti AL, Drummond PD, Inarejos-Garcia AM, Prodanov M (2018). affron, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: a randomised, double-blind, placebo-controlled study. Journal of Affective Disorders. link
- 5Agha-Hosseini M, Kashani L, Aleyaseen A, et al. (2008). Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG. link
- 6Modabbernia A, Sohrabi H, Nasehi AA, et al. (2012). Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology. link
- 7Kashani L, Raisi F, Saroukhani S, et al. (2013). Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Human Psychopharmacology. link
- 8Hosseinzadeh H, Nassiri-Asl M (2014). Avicenna's view on saffron: pharmacological and toxicological aspects. Iranian Journal of Basic Medical Sciences. link
- 9Petrosino M, Stellavato A, La Gatta A, et al. (2024). Saffron adulteration: market detection and authentication via DNA barcoding, HPLC and chromatographic fingerprinting. Food Chemistry. link
Saffron
Two capsules a day with food. The only ongoing effort is remembering to take it; the 6–8-week response window means a real trial requires sustained adherence rather than a one-off.
Standardised extracts (affron, Satiereal) run $12–20/month, ~$150–250/year. Falls in the minor band — not negligible but well below most other supplement subscriptions.
Multiple RCTs at 30 mg/day for 6 weeks show saffron outperforms placebo on the Hamilton Depression Rating Scale and is non-inferior to fluoxetine 20 mg and imipramine in mild-to-moderate depression (Akhondzadeh 2005, Noorbala 2005, Lopresti 2014 review, Marx 2019 meta-analysis of 11 RCTs). Clear stabilisation of inner life in the responder; not transformative (severe MDD untested).
Multiple small-to-moderate RCTs and at least one solid meta-analysis (Marx et al. 2019, 11 RCTs) for depression and PMS; mechanistic plausibility (MAO-A inhibition, monoamine reuptake, BDNF). Held back from 4 by regional clustering of trials in Iran, small per-trial sample sizes (mostly n=30–60/arm), and no guideline-level recommendation.
Within weeks, the documented felt effects are large reductions in PMS symptom severity at 30 mg/day (Agha-Hosseini et al. 2008: 76% achieved ≥50% symptom reduction vs 8% on placebo) and rescue of SSRI-induced sexual dysfunction in both sexes (Kashani 2013, Modabbernia 2012). Real day-to-day functional improvement for the indication subgroups, not a general wellness lift.
Lopresti et al. 2020 (n=63, 28 days) showed affron 28 mg/day improved Insomnia Severity Index and Restorative Sleep Questionnaire scores vs placebo; a follow-on dose-finding RCT replicated. Real but single-research-group evidence base; modest effect.